Shots:
- The US FDA has approved Valtoco for short-term treatment of acute repetitive seizures (seizure clusters) in pts (≥2yrs.) with epilepsy
- Approval was based on P-I/IIa trial assessing safety & PK of Valtoco, which showed favorable safety & efficacy with easy administration in pts who had episodes of frequent seizures; data was presented at CNS 2024 & AES 2024
- Valtoco is a proprietary diazepam formulation that utilizes Intravail tech to improve non-invasive intranasal absorption & delivery for acute treatment of intermittent, stereotypic seizure episodes distinct from a pts’s usual pattern
Ref: Prnewswire | Image: Neurelis
Related News:- Eisai, Biogen and BioArctic Report the EC’s Approval of Leqembi (lecanemab) for Early Alzheimer’s Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
